Diamyd Medical partners with JDRF to advance the DIAGNODE-3 Phase 3 trial in Type 1 Diabetes - Marketscreener.com
| DMYD-B Stock | SEK 13.60 0.62 4.78% |
About 54% of Diamyd Medical's investors are presently thinking to get in. The analysis of current outlook of investing in Diamyd Medical AB suggests that some traders are interested regarding Diamyd Medical's prospects. The current market sentiment, together with Diamyd Medical's historical and current headlines, can help investors time the market. In addition, many technical investors use Diamyd Medical AB stock news signals to limit their universe of possible portfolio assets.
Diamyd |
Diamyd Medical partners with JDRF to advance the DIAGNODE-3 Phase 3 trial in Type 1 Diabetes Marketscreener.com
Read at news.google.com
 |
Diamyd Medical Fundamental Analysis
We analyze Diamyd Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diamyd Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diamyd Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Diamyd Medical is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Diamyd Medical AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Diamyd Medical stock to make a market-neutral strategy. Peer analysis of Diamyd Medical could also be used in its relative valuation, which is a method of valuing Diamyd Medical by comparing valuation metrics with similar companies.
Peers
Diamyd Medical Related Equities
| EXPRS2 | ExpreS2ion Biotech | 9.85 | ||||
| SANION | Saniona AB | 2.14 | ||||
| HNSA | Hansa Biopharma | 0.12 | ||||
| ONCO | Oncopeptides | 2.37 |
Complementary Tools for Diamyd Stock analysis
When running Diamyd Medical's price analysis, check to measure Diamyd Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamyd Medical is operating at the current time. Most of Diamyd Medical's value examination focuses on studying past and present price action to predict the probability of Diamyd Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diamyd Medical's price. Additionally, you may evaluate how the addition of Diamyd Medical to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |